AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, is expanding the scope and ...

BRISBANE, Australia & INDIANAPOLIS--(BUSINESS WIRE)--AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an expansion to the scope and ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...

Australian clinical-stage radiopharmaceutical company AdvanCell has announced an expansion to the scope and breadth of its ...

Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...

We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...

AdvanCell is developing therapies to treat cancers including: prostate, skin, pancreatic, breast, bladder, colorectal, kidney ...

AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an expansion to the scope and breadth of its strategic collaboration with Eli Lilly ...

BRISBANE, Australia & INDIANAPOLIS, February 10, 2025--(BUSINESS WIRE)--AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an ...

On Monday, Eli Lilly And Co (NYSE:LLY) inked two strategic collaborations to expand radiopharmaceuticals and metabolic-associated steatohepatitis (MASH), respectively. AdvanCell announced that it ...